How IL-6/STAT3 helps CIC-DUX4 sarcoma spread and hide from the immune system
Official title: The role of IL-6/STAT3 signaling in CIC-DUX4 fusion sarcoma metastasis and immunosuppression
Funded at Beckman Research Institute/city of Hope · NIH-11311805 · Data updated 2026-11-12
Researchers will target the IL-6/STAT3 signaling pathway in CIC-DUX4 fusion sarcoma to look for ways to stop cancer spread in children and young adults.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | April 3, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $573,528 |
| NIH project number | 5R01CA299039-02 |
| Project ID | NIH-11311805 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children, adolescents, and young adults diagnosed with CIC-DUX4 fusion-positive sarcoma would be the most relevant candidates for related trials or sample donation.
✕Less likely to help
Patients who have other types of sarcoma without the CIC-DUX4 fusion or unrelated cancers are unlikely to benefit directly from this specific line of research.
What this research studies
This project studies an aggressive childhood sarcoma driven by the CIC-DUX4 fusion and focuses on a cell signal called IL-6/STAT3 that appears to help tumors survive, change their metabolism, and attract immune cells that suppress anti-cancer responses. Scientists will use laboratory models, tumor specimens, and animal experiments to see how the fusion protein turns on IL-6/STAT3 and how that affects cancer stem-cell features and lipid metabolism. The team will also examine how tumors recruit tumor-associated macrophages and immunosuppressive T cells and test whether blocking IL-6/STAT3 reverses these effects. Results could point to treatments that reduce metastasis and restore anti-tumor immunity for young patients with this fusion-positive sarcoma.
Why it matters
Potential benefit: If successful, this work could lead to therapies that block IL-6/STAT3 signaling and reduce metastasis and immune suppression in children and young adults with CIC-DUX4 sarcoma.
How similar studies have gone: Targeting IL-6/STAT3 has shown promise in some other cancer types, but applying this approach specifically to CIC-DUX4 fusion sarcoma is new and not yet tested in patients.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Yu, Hua E — Beckman Research Institute/city of Hope
- Study coordinator: Yu, Hua E
Related research
Other NIH-funded projects on the same topics.
-
Investigating how a specific cancer fusion protein affects tumor growth and immune response in a rare type of sarcoma.
This study is looking into how a specific protein linked to a rare and aggressive cancer called CIC-DUX4 fusion-positive sarcoma helps the cancer grow and spread, with the goal of finding new ways to treat patients and improve their outcomes.
-
TGFβ brakes immune evasion and metastasis in Ewing sarcoma during radiation
A physician-scientist will study whether blocking TGFβ during radiation can help CAR T cells fight Ewing sarcoma and improve patient outcomes.
-
Fibroblasts in brain metastases help cancer grow and hide from treatment
In people with cancer that has spread to the brain, researchers are studying how lung cancer–driven fibroblasts in the brain help cancer cells grow, resist standard therapies, and dampen the immune response.
-
How some p53 gene changes help head and neck cancers spread and hide from the immune system
Researchers are looking at whether blocking a protein called MCM5 can stop p53‑mutant head and neck cancers from becoming unstable, spreading, and weakening the immune system.
-
Fibroblasts help cancer cells grow in the brain and resist treatment.
This study is looking at how certain cells in the body, called fibroblasts, help lung cancer spread to the brain and may make it harder for treatments to work, with the goal of finding new ways to help patients with brain metastases feel better.
-
Targeting cells that cause cancer spread in a specific type of sarcoma
This study is looking at a specific type of soft tissue cancer called undifferentiated pleomorphic sarcoma (UPS) to find out how certain cells help it spread, with the goal of creating new treatments that can stop this spread and help patients like you.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.